

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

Original Issue Date (Created):	8/9/2002
Most Recent Review Date (Revised):	4/10/2020
Effective Date:	7/1/2020

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

The use of carbon-coated spheres (Durasphere®), calcium hydroxylapatite (CaHA) (Coaptite®) or polydimethylsiloxane (Macroplastique®) may be considered **medically necessary** to treat urinary stress incontinence in men and women who have failed conservative therapy.

The use of autologous cellular therapy (e.g., myoblasts, fibroblasts, muscle-derived stem cells, or adipose-derived stem cells), autologous fat, and autologous ear chondrocytes to treat stress urinary incontinence is considered **investigational**.

The use of any other periurethral bulking agent, including, but not limited to Teflon®, to treat stress urinary incontinence is considered **investigational**.

The use of periurethral bulking agents to treat urge urinary incontinence is considered **investigational**.

The use of perianal bulking agents to treat fecal incontinence is considered **investigational**.

There is insufficient evidence to support a conclusion concerning the health outcomes related to their efficacy for the above listed investigational indications.

Policy Guidelines

Patients should have had inadequate response to conservative therapy or therapies; in general, these treatments should have been used for at least 3 months. Conservative therapy for stress incontinence includes pelvic floor muscle exercises and behavioral changes, such as fluid management and moderation of physical activities that provoke incontinence. Additional options include intravaginal estrogen therapy, use of a pessary, and treatment of other underlying causes of incontinence in patients amenable to these treatments.

Cross-references

MP-1.033 Sacral Nerve Modulation/Stimulation and Pelvic Floor Stimulation Devices

MP-1.134 Percutaneous Tibial Nerve Stimulation

MP-2.064 Biofeedback and Neurofeedback Therapy

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

MP-4.034 Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence

II. PRODUCT VARIATIONS

[Top](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO - Refer to FEP Medical Policy Manual MP 7.01.19, Periurethral Bulking Agents for the Treatment of Urinary and Fecal Incontinence. The FEP Medical Policy Manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

III. DESCRIPTION/BACKGROUND

[Top](#)

Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally to treat urinary incontinence and perianally to treat fecal incontinence. The U.S. Food and Drug Administration (FDA) has approved several bulking agent products for treating urinary incontinence and one for treating fecal incontinence

Injectable bulking agents are space-filling substances used to increase tissue bulk. When used to treat stress urinary incontinence (SUI), bulking agents are injected periurethrally to increase the tissue bulk and thereby increase resistance to the outflow of urine. The bulking agent is injected into the periurethral tissue as a liquid that then solidifies into a spongy material to bulk the urethral wall. Bulking agents may be injected over a course of several treatments until the desired effect is achieved. Periurethral bulking agents have been widely used for incontinence in women. Men have also been treated, typically those with post-prostatectomy incontinence.

Following the success of periurethral bulking agents for treating SUI, bulking agents injected into the anal canal have been proposed for treating fecal incontinence. In particular, bulking agents are a potential treatment for passive fecal incontinence associated with internal anal sphincter (IAS) dysfunction. The bulking agent is injected into the submucosa of the anal canal to increase tissue bulk in the area, which narrows the opening of the anus. Current treatment options for fecal incontinence include conservative measures e.g., dietary changes, pharmacotherapy and pelvic floor muscle exercises, sacral nerve stimulation, and surgical interventions to correct an underlying problem.

Key factors in determining the optimal product are biocompatibility, durability, and absence of migration. A number of periurethral bulking agents to treat urinary incontinence have been cleared for marketing by the Food and Drug Administration (FDA); however, products developed to date have not necessarily met all criteria of the ideal bulking agents. The first FDA-

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

approved product was cross-linked collagen (e.g., Contigen). The agent was found to be absorbed over time and symptoms could recur, requiring additional injections. Contigen production was discontinued in 2011. Other periurethral bulking agents cleared by FDA for urinary incontinence include carbon-coated beads (e.g., Durasphere), spherical particles of calcium hydroxylapatite (CaHA) in a gel carrier (Coaptite), polydimethylsiloxane (silicone, Macroplastique), and ethylene vinyl alcohol copolymer implants (e.g., Tegress, formerly Uryx). Tegress was voluntarily removed from the market due to safety concerns.

Several agents identical to or similar to those used for urinary incontinence e.g., Durasphere, silicone biomaterial, etc. have been studied for the treatment of fecal incontinence. To date, only one bulking agent has been approved by the FDA for treating fecal incontinence. This is a formulation of non-animal stabilized hyaluronic acid/dextranomer in stabilized hyaluronic acid (NASHA Dx) and is marketed by Q-Med as Solesta. A hyaluronic acid/dextranomer formulation (Deflux™) from the same company has been commercially available for a number of years for the treatment of vesicoureteral reflux in children

Autologous fat and autologous ear chondrocytes have also been used as periurethral bulking agents; autologous substances do not require FDA approval. Polytetrafluoroethylene (Teflon®) has been investigated as an implant material but has not received FDA approval. A more recently explored alternative is cellular therapy with myoblasts, fibroblasts, or stem cells (muscle-derived or adipose-derived). In addition to their use as periurethral bulking agents, it is hoped that transplanted stem cells will undergo self-renewal and multipotent differentiation, which could result in regeneration of the sphincter and its neural connections.

Regulatory Status

Several periurethral bulking agents have been approved by the FDA through the premarket approval process. These devices are indicated for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency; other than Contigen, approval is only for use in adult women. Products include:

- In 1993, Contigen (Allergan, Inc.), a cross-linked collagen, was approved. A supplemental approval in 2009 limited the device’s indication to treatment of urinary incontinence due to intrinsic sphincter deficiency in patients (men or women) who have shown no improvement in incontinence for at least 12 months. The manufacturer of the product ceased production in 2011; no reason for discontinuation was provided to the public.
- In 1999, Durasphere (Advanced UroScience), pyrolytic carbon-coated zirconium oxide spheres, was approved.
- In 2004, Uryx (CR Bard), vinyl alcohol copolymer implants, was approved. In 2005, approval was given to market the device under the trade name Tegress. In 2007, Tegress was voluntarily removed from the market due to safety concerns.
- In 2005, Coaptite (Merz Aesthetics, previously BioForm Medical), spherical particles of calcium hydroxylapatite, suspended in a gel carrier, was approved
- In 2006, Macroplastique (Cogentix Medical), polydimethylsiloxane, was approved.

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

In 2011, NASHA Dx, marketed as Solesta® (Q-Med), was approved by FDA through the premarket approval process as a bulking agent to treat fecal incontinence in patients 18 years and older who have failed conservative therapy. FDA product code: LNM.

IV. RATIONALE

[Top](#)

Summary of Evidence

For individuals who have stress urinary incontinence who receive injectable bulking agents, the evidence includes randomized controlled trials (RCTs) and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Studies have shown that cross-linked collagen improves the net health outcome (i.e., it is effective in some patients who failed conservative treatment with fewer adverse events than surgery), although this product is no longer commercially available. There is evidence that Food and Drug Administration (FDA) FDA-approved carbon-coated spheres, calcium hydroxylapatite, and polydimethylsiloxane have efficacy for treating incontinence and produce outcomes and have a safety profile similar to cross-linked collagen. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

For individuals who have fecal incontinence who receive injectable bulking agents, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A comparative effectiveness review from the Agency for Healthcare Research and Quality evaluated 2 RCTs with the FDA-approved product NASHA Dx (Solesta) and 2 RCTs with Durasphere (off-label in the United States). One RCT comparing NASHA Dx with sham found that NASHA Dx improved some outcome measures but not others. The other RCT did not find a significant difference in efficacy between NASHA Dx and biofeedback. Two additional RCTs evaluating Durasphere found only short-term improvements in fecal incontinence severity. Controlled trials with longer follow-up are important to determine the durability of any treatment effect. The evidence is insufficient to determine the effects of the technology on health outcomes.

V. DEFINITIONS

[Top](#)

510(K) APPROVAL refers to section 510(k) of the Food, Drug and Cosmetic Act. Under 510(k), before a manufacturer can market a medical device in the United States, they must demonstrate to FDA’s satisfaction that it is substantially equivalent (as safe and effective) to a device already on the market.

MIXED INCONTINENCE is a combination of stress and urge incontinence.

OVERFLOW INCONTINENCE is characterized by small frequent voidings due to overfilling of the bladder or to a bladder with pathologically decreased volume.

PESSARY is a device inserted into the vagina to function as a support structure for the uterus.

STRESS INCONTINENCE is an involuntary loss of urine that occurs during physical activity, such as coughing, sneezing, laughing or exercise. This incontinence occurs as a result of weakened

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

pelvic muscles that support the bladder and urethra, or because of malfunction of the urethral sphincter.

URGE INCONTINENCE is a condition characterized by a strong desire to urinate immediately before an involuntary bladder contraction with a loss of a large amount of urine.

VI. BENEFIT VARIATIONS

[Top](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital BlueCross. Members and providers should consult the member's health benefit plan for information or contact Capital BlueCross for benefit information.

VII. DISCLAIMER

[Top](#)

Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital BlueCross' Provider Services or Member Services. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[Top](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

Investigational; therefore, not covered:

HCPCS Code	Description
L8605	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies

Covered when medically necessary:

CPT Codes®							
51715							

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

HCPCS Code	Description
L8603	Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies
L8606	Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies

ICD-10-CM Diagnosis Code	Description
N36.41	Hypermobility of urethra
N36.42	Intrinsic sphincter deficiency (ISD)
N36.43	Combined hypermobility of urethra and intrinsic sphincter deficiency
N36.8	Other specified disorders of urethra
N39.3	Stress incontinence (female) (male)
N39.4	Other specified urinary incontinence
N39.46	Mixed incontinence (urge and stress incontinence)

IX. REFERENCES

[Top](#)

1. Gorina Y, Schappert S, Bercovitz A, et al. Prevalence of incontinence among older Americans. *Vital Health Stat 3. Jun 2014(36):1-33. PMID 24964267*
2. Kirchin V, Page T, Keegan PE, et al. Urethral injection therapy for urinary incontinence in women. *Cochrane Database Syst Rev. Feb 15 2012;2(2):CD003881. PMID 22336797*
3. Davila GW. Nonsurgical outpatient therapies for the management of female stress urinary incontinence: long-term effectiveness and durability. *Adv Urol. 2011;2011:176498. PMID 21738529*
4. Agency for Health Care Policy and Research. *Clinical Practice Guideline. Urinary Incontinence in Adults. Rockville, MD: Department of Health and Human Services; 1996.*

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

5. Corcos J, Collet JP, Shapiro S, et al. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. *Urology*. May 2005;65(5):898-904. PMID 15882720
6. Lightner D, Calvosa C, Andersen R, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. *Urology*. Jul 2001;58(1):12-15. PMID 11445471
7. Hurtado E, McCreary R, Appell R. The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic urethral deficiency. *Int Urogynecol J Pelvic Floor Dysfunct*. Aug 2007;18(8):869-873. PMID 17103121
8. Food and Drug Administration. Summary of Safety and Effectiveness: URYX Urethral Bulking Agent. 2004; https://www.accessdata.fda.gov/cdrh_docs/pdf3/P030030b.pdf. Accessed April 10, 2020.
9. Mayer RD, Dmochowski RR, Appell RA, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. *Urology*. May 2007;69(5):876-880. PMID 17482925
10. Ghoniem G, Corcos J, Comiter C, et al. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. *J Urol*. Jan 2009;181(1):204-210. PMID 19013613
11. Ghoniem G, Corcos J, Comiter C, et al. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. *J Urol*. Apr 2010;183(4):1444-1449. PMID 20171691
12. Lightner D, Rovner E, Corcos J, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. *Urology*. Oct 2009;74(4):771-775. PMID 19660800
13. Chapple CR, Haab F, Cervigni M, et al. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence. *Eur Urol*. Sep 2005;48(3):488-494. PMID 15967568
14. Lone F, Sultan AH, Thakar R. Long-term outcome of transurethral injection of hyaluronic acid/dextranomer (NASHA/Dx gel) for the treatment of stress urinary incontinence (SUI). *Int Urogynecol J*. Nov 2010;21(11):1359-1364. PMID 20571764
15. Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. *J Urol*. Sep 2014;192(3):843-849. PMID 24704117
16. Pai A, Al-Singary W. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid((R))) in the management of stress and mixed urinary incontinence: three year follow up outcomes. *Cent European J Urol*. Feb 2015;68(4):428-433. PMID 26855795
17. Lose G, Sorensen HC, Axelsen SM, et al. An open multicenter study of polyacrylamide hydrogel (Bulkamid(R)) for female stress and mixed urinary incontinence. *Int Urogynecol J*. Dec 2010;21(12):1471-1477. PMID 20645077
18. Leone Roberti Maggiore U, Alessandri F, Medica M, et al. Outpatient periurethral injections of polyacrylamide hydrogel for the treatment of female stress urinary incontinence: effectiveness and safety. *Arch Gynecol Obstet*. Jul 2013;288(1):131-137. PMID 23371485

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

19. Mouritsen L, Lose G, Moller-Bek K. Long-term follow-up after urethral injection with polyacrylamide hydrogel for female stress incontinence. *Acta Obstet Gynecol Scand.* Feb 2014;93(2):209-212. PMID 24372312
20. Lee PE, Kung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. *J Urol.* Jan 2001;165(1):153-158. PMID 11125386
21. Bent AE, Tutrone RT, McLennan MT, et al. Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent. *Neurourol Urodyn.* 2001;20(2):157-165. PMID 11170190
22. Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. *Lancet.* Jun 30 2007;369(9580):2179-2186. PMID 17604800
23. Kleinert S, Horton R. Retraction--autologous myoblasts and fibroblasts versus collagen [corrected] for treatment of stress urinary incontinence in women: a [corrected] randomised controlled trial. *Lancet.* Sep 6 2008;372(9641):789-790. PMID 18774408
24. Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. *J Urol.* Aug 2014;192(2):469-476. PMID 24582537
25. Forte ML, Andrade KE, Butler M, et al. Treatments for Fecal Incontinence (Comparative Effectiveness Review No. 165). Rockville, MD: Agency for Healthcare Research and Quality; 2016.
26. Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. *Cochrane Database Syst Rev.* Feb 28 2013;2(2):CD007959. PMID 23450581
27. Hussain ZI, Lim M, Stojkovic SG. Systematic review of perianal implants in the treatment of faecal incontinence. *Br J Surg.* Nov 2011;98(11):1526-1536. PMID 21964680
28. Leung FW. Treatment of fecal incontinence - review of observational studies (OS) and randomized controlled trials (RCT) related to injection of bulking agent into peri-anal tissue. *J Interv Gastroenterol.* Oct 2011;1(4):202-206. PMID 22586538
29. Graf W, Mellgren A, Matzel KE, et al. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. *Lancet.* Mar 19 2011;377(9770):997-1003. PMID 21420555
30. Dehli T, Stordahl A, Vatten LJ, et al. Sphincter training or anal injections of dextranomer for treatment of anal incontinence: a randomized trial. *Scand J Gastroenterol.* Mar 2013;48(3):302-310. PMID 23298304
31. Morris OJ, Smith S, Draganic B. Comparison of bulking agents in the treatment of fecal incontinence: a prospective randomized clinical trial. *Tech Coloproctol.* Oct 2013;17(5):517-523. PMID 23525964
32. La Torre F, de la Portilla F. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence. *Colorectal Dis.* May 2013;15(5):569-574. PMID 23374680
33. Kobashi KC, Albo ME, Dmochowski RR, et al. Surgical treatment of female stress urinary incontinence: AUA/SUFU Guideline. *J Urol.* Oct 2017;198(4):875-883. PMID 28625508

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

34. Chapple CR, Cruz F, Deffieux X, et al. Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. *Eur Urol.* Sep 2017;72(3):424-431. PMID 28413126
35. Lovatsis D, Easton W, Wilkie D, et al. Guidelines for the evaluation and treatment of recurrent urinary incontinence following pelvic floor surgery. *J Obstet Gynaecol Can.* Sep 2010;32(9):893-904. PMID 21050525
36. National Institute for Health and Care Excellence (NICE). Urinary incontinence in women: management [CG171]. 2015; <https://www.nice.org.uk/guidance/CG171/chapter/introduction>. Accessed April 10, 2020 .
37. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 155: Urinary Incontinence in Women. *Obstet Gynecol.* May 2016;127(5):e66-81. PMID 27548423
38. Paquette IM, Varma MG, Kaiser AM, et al. The American Society of Colon and Rectal Surgeons' clinical practice guideline for the treatment of fecal incontinence. *Dis Colon Rectum.* Jul 2015;58(7):623-636. PMID 26200676
39. National Institute for Health and Care Excellence (NICE). Injectable bulking agents for faecal incontinence [IPG210]. 2007; <https://www.nice.org.uk/guidance/ipg210/chapter/1-guidance>. Accessed April 12, 2019.
40. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Incontinence Control Devices (230.10). 1996; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=241&ncdver=1&DocID=230.10&bc=gAAAAAgAAAAAA%3D%3D&> Accessed April 10, 2020 .
41. Blue Cross Blue Shield Association Medical Policy Reference Manual. 7.01.19, Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence. September 2019.

Other Sources:

1. Taber’s Cyclopedic Medical Dictionary, 19th edition

X. POLICY HISTORY

[Top](#)

MP 4.012	CAC 6/29/04
	CAC 12/14/04
	CAC 1/31/06
	CAC 2/27/07
	CAC 1/29/08
	CAC 3/31/09
	CAC 3/30/10 Consensus Review
	CAC 4/26/11 Adopted BCBSA. Added statement that the use of periurethral bulking agents to treat urge urinary incontinence is considered investigational. Background/description regarding periurethral bulking agents was revised to reflect current available agents. Policy statements regarding carbon-coated spheres were revised

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

	as Tegress was previously withdrawn from the market. BCBSA criteria for periurethral bulking agents and transvaginal and transurethral radiofrequency tissue remodeling for urinary stress incontinence were adopted. A Medicare variation was added to the policy for collagen implants. Information related to EMGs and non-surgical/non-pharmacological urinary incontinence therapy related to diagnoses was removed from the policy.
	CAC 6/26/12 Consensus. No change to policy statements. Added BCBSA’s Background /Description for Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence
	7/29/13 Admin coding review complete
	CAC 9/24/13 Minor. Policy title changed – formally titled Urinary Incontinence Treatment (Including Periurethral Bulking Agents). Added investigational statement “The use of perianal bulking agents to treat fecal incontinence is considered investigational”. Extracted information regarding transvaginal and transurethral radiofrequency tissue remodeling for urinary stress incontinence and a separate policy created - MP 4.034 Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence. Added rationale section.
	CAC 7/22/14 Consensus review. No changes to the policy statements. References and rationale updated.
	CAC 7/21/15 Consensus review. Cross-linked collagen (Contigen®) is no longer available - no reason for discontinuation was provided to the public. Information removed from the policy. No other changes to the policy statements. Rationale and references updated. Coding reviewed.
	CAC 7/26/16 Consensus review. No change to policy statements. References and rationale reviewed. Coding reviewed.
	Admin update 1/1/17: Product variation section reformatted.
	CAC 9/26/17 Consensus. No change to policy statements. References and rationale updated. Coding Reviewed.
	1/1/18 Admin Update: Medicare variations removed from Commercial Policies.
	5/1/18 Coding reviewed. L8604 removed from policy.
	6/11/18 Consensus review. No change to policy statements. References updated. Rationale condensed.
	4/12/2019 Consensus Review. No changes to policy statements. Updated references.
	1/1/2020 Coding update. Removing deleted code 0377T.
	4/10/2020 Consensus. No change to policy statement. References, rationale and coding updated.

POLICY TITLE	INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
POLICY NUMBER	MP- 4.012

[TOP](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies